The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu

Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03707509
Recruitment Status : Active, not recruiting
First Posted : October 16, 2018
Last Update Posted : July 1, 2022
Information provided by (Responsible Party):
Jiangsu HengRui Medicine Co., Ltd.